Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

Hassane M. Zarour, John M. Kirkwood, Lisa Salvucci Kierstead, Wolfgang Herr, Vladimir Brusic, Craig L. Slingluff, John Sidney, Alessandro Sette, Walter J. Storkus

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

The human Melan-A/MART-1 gene encodes an HLA-A2-restricted peptide epitope recognized by melanoma-reactive CD8+ cytotoxic T lymphocytes. Here we report that this gene also encodes at least one HLA-DR4-presented peptide recognized by CD4+ T cells. The Melan-A/MART-151-73 peptide was able to induce the in vitro expansion of specific CD4+ T cells derived from normal DR4+ donors, or from DR4+ patients with melanoma when pulsed onto autologous dendritic cells. CD4+ responder T cells specifically produced IFN-γ in response to, and also lysed, T2.DR4 cells pulsed with the Melan- A/MART-151-73 peptide and DR4+ melanoma target cells naturally expressing the Melan-A/MART-1 gene product. Interestingly, CD4+ T cell immunoreactivity against the Melan-A/MART-151-73 peptide typically coexisted with a high frequency of anti-Melan-A/MART-127-35 reactive CD8+ T cells in freshly isolated blood harvested from HLA-A2+/DR4+ patients with melanoma. Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.

Original languageEnglish
Pages (from-to)400-405
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume97
Issue number1
DOIs
Publication statusPublished - Jan 4 2000
Externally publishedYes

Fingerprint

MART-1 Antigen
HLA-DR4 Antigen
Epitopes
Melanoma
T-Lymphocytes
Peptides
HLA-A2 Antigen
Genes
Cytotoxic T-Lymphocytes
Dendritic Cells
Tissue Donors

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells. / Zarour, Hassane M.; Kirkwood, John M.; Kierstead, Lisa Salvucci; Herr, Wolfgang; Brusic, Vladimir; Slingluff, Craig L.; Sidney, John; Sette, Alessandro; Storkus, Walter J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, No. 1, 04.01.2000, p. 400-405.

Research output: Contribution to journalArticle

Zarour, Hassane M. ; Kirkwood, John M. ; Kierstead, Lisa Salvucci ; Herr, Wolfgang ; Brusic, Vladimir ; Slingluff, Craig L. ; Sidney, John ; Sette, Alessandro ; Storkus, Walter J. / Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells. In: Proceedings of the National Academy of Sciences of the United States of America. 2000 ; Vol. 97, No. 1. pp. 400-405.
@article{e45926e74801458f8a427ff9f3c6ccf4,
title = "Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells",
abstract = "The human Melan-A/MART-1 gene encodes an HLA-A2-restricted peptide epitope recognized by melanoma-reactive CD8+ cytotoxic T lymphocytes. Here we report that this gene also encodes at least one HLA-DR4-presented peptide recognized by CD4+ T cells. The Melan-A/MART-151-73 peptide was able to induce the in vitro expansion of specific CD4+ T cells derived from normal DR4+ donors, or from DR4+ patients with melanoma when pulsed onto autologous dendritic cells. CD4+ responder T cells specifically produced IFN-γ in response to, and also lysed, T2.DR4 cells pulsed with the Melan- A/MART-151-73 peptide and DR4+ melanoma target cells naturally expressing the Melan-A/MART-1 gene product. Interestingly, CD4+ T cell immunoreactivity against the Melan-A/MART-151-73 peptide typically coexisted with a high frequency of anti-Melan-A/MART-127-35 reactive CD8+ T cells in freshly isolated blood harvested from HLA-A2+/DR4+ patients with melanoma. Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.",
author = "Zarour, {Hassane M.} and Kirkwood, {John M.} and Kierstead, {Lisa Salvucci} and Wolfgang Herr and Vladimir Brusic and Slingluff, {Craig L.} and John Sidney and Alessandro Sette and Storkus, {Walter J.}",
year = "2000",
month = "1",
day = "4",
doi = "10.1073/pnas.97.1.400",
language = "English",
volume = "97",
pages = "400--405",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "1",

}

TY - JOUR

T1 - Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells

AU - Zarour, Hassane M.

AU - Kirkwood, John M.

AU - Kierstead, Lisa Salvucci

AU - Herr, Wolfgang

AU - Brusic, Vladimir

AU - Slingluff, Craig L.

AU - Sidney, John

AU - Sette, Alessandro

AU - Storkus, Walter J.

PY - 2000/1/4

Y1 - 2000/1/4

N2 - The human Melan-A/MART-1 gene encodes an HLA-A2-restricted peptide epitope recognized by melanoma-reactive CD8+ cytotoxic T lymphocytes. Here we report that this gene also encodes at least one HLA-DR4-presented peptide recognized by CD4+ T cells. The Melan-A/MART-151-73 peptide was able to induce the in vitro expansion of specific CD4+ T cells derived from normal DR4+ donors, or from DR4+ patients with melanoma when pulsed onto autologous dendritic cells. CD4+ responder T cells specifically produced IFN-γ in response to, and also lysed, T2.DR4 cells pulsed with the Melan- A/MART-151-73 peptide and DR4+ melanoma target cells naturally expressing the Melan-A/MART-1 gene product. Interestingly, CD4+ T cell immunoreactivity against the Melan-A/MART-151-73 peptide typically coexisted with a high frequency of anti-Melan-A/MART-127-35 reactive CD8+ T cells in freshly isolated blood harvested from HLA-A2+/DR4+ patients with melanoma. Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.

AB - The human Melan-A/MART-1 gene encodes an HLA-A2-restricted peptide epitope recognized by melanoma-reactive CD8+ cytotoxic T lymphocytes. Here we report that this gene also encodes at least one HLA-DR4-presented peptide recognized by CD4+ T cells. The Melan-A/MART-151-73 peptide was able to induce the in vitro expansion of specific CD4+ T cells derived from normal DR4+ donors, or from DR4+ patients with melanoma when pulsed onto autologous dendritic cells. CD4+ responder T cells specifically produced IFN-γ in response to, and also lysed, T2.DR4 cells pulsed with the Melan- A/MART-151-73 peptide and DR4+ melanoma target cells naturally expressing the Melan-A/MART-1 gene product. Interestingly, CD4+ T cell immunoreactivity against the Melan-A/MART-151-73 peptide typically coexisted with a high frequency of anti-Melan-A/MART-127-35 reactive CD8+ T cells in freshly isolated blood harvested from HLA-A2+/DR4+ patients with melanoma. Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4+ T cell responses against melanoma in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0034602674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034602674&partnerID=8YFLogxK

U2 - 10.1073/pnas.97.1.400

DO - 10.1073/pnas.97.1.400

M3 - Article

VL - 97

SP - 400

EP - 405

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 1

ER -